Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have idiopathic PD (by standard clinical criteria).~2. Patients must have persistence of LID despite optimization of anti-Parkinsonian medication (duration of LID \> 1 \[duration of at least 1-25% of the waking time\] on item 32 of the United Parkinson's Disease Rating Scale \[UPDRS\]).~3. Patients must have severity of LID \> 1 \[mildly disabling\] on item 33 of the UPDRS.~4. Patients must have a Mini-Mental State score of \> 24.~5. Patients must be willing and able to give consent.~Exclusion Criteria:~1. Patients who are older than 75 years of age.~2. Patients who have a Parkinsonian syndrome that is unresponsive or weakly responsive to levodopa (improvement \< 30%).~3. Patients who require concurrent use of warfarin or other anticoagulating agents.~4. Uncontrolled clinically significant medical condition other than the condition under evaluation~5. Known allergy or sensitivity to any of the components in the study medication.~6. Concurrent participation in another investigational drug or device study or participation in the 30 days immediately prior to study enrollment.~7. Any medical condition that may put the subject at an increased risk with exposure to Botox including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function.~8. Evidence of recent alcohol or drug abuse.~9. Infection or skin disorder at an anticipated injection site (if applicable).~10. Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Botox (Type: EXPERIMENTAL): Randomized into receiving Botox first. At cross-over, patients will receive placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Randomized to receive placebo first. At cross-over, patients will receive the active Botox.

Based on this trial design, predict the completion outcome and termination type (if applicable).